Biogen, Ionis will discontinue development of their ALS drug-June 2024-www.financetom.com

Biogen, Ionis will discontinue development of their ALS drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Biogen, Ionis will discontinue development of their ALS drug

May 16, 2024 5:05 AM

May 16 (Reuters) - Biogen and Ionis

Pharmaceuticals ( IONS ) said on Thursday they will terminate

the development of their treatment for amyotrophic lateral

sclerosis (ALS) based on results from an early-stage study.

Previous page： Skydance asks Paramount to stop negotiating with Bronfman, WSJ reports Next page： Uber To Bring GM's Cruise Autonomous Vehicles To Its Platform

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Skydance asks Paramount to stop negotiating with Bronfman, WSJ reports

Aug 24, 2024

(Reuters) -Skydance Media is accusing Paramount Global's ( PARAA ) special committee of directors of breaching the terms of its deal by extending the period of time when it can engage with other bidders, the Wall Street Journal reported on Thursday. This comes after veteran media executive Edgar Bronfman Jr sweetened his bid to take over Paramount offering $6 billion...

Uber To Bring GM's Cruise Autonomous Vehicles To Its Platform

Aug 24, 2024

Uber Technologies, Inc. ( UBER ) and General Motors Company's ( GM )Cruise announced on Thursday a multiyear strategic partnership to bring Cruise autonomous vehicles to the Uber ( UBER ) platform. The Details: The companies plan to launch the partnership next year with a dedicated number of Chevy Bolt-based autonomous vehicles. Once the program is launched, an Uber (...

--Teradyne Keeps Quarterly Dividend at $0.12 per Share, Payable Sept. 27 to Shareholders of Record on Sept. 5

Aug 24, 2024

05:26 PM EDT, 08/22/2024 (MT Newswires) -- Price: 132.57, Change: +1.37, Percent Change: +1.04 ...

Core Molding Technologies Insider Sold Shares Worth $523,859, According to a Recent SEC Filing

Aug 24, 2024

06:01 PM EDT, 08/22/2024 (MT Newswires) -- David L. Duvall, Director, Chief Executive Officer, on August 20, 2024, sold 29,150 shares in Core Molding Technologies ( CMT ) for $523,859. Following the Form 4 filing with the SEC, Duvall has control over a total of 358,227 shares of the company, with 358,227 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1026655/000102665524000104/xslF345X05/wk-form4_1724363812.xml Price: 17.85,...